Interleukin-17A (IL-17A) and IL-17F are critical for antimicrobial peptide production and clearance of Staphylococcus aureus nasal colonization

Infection and Immunity

Volumn 84, Issue 12, 2016, Pages 3575-3583

  Archer, Nathan K ^a,b,c   Adappa, Nithin D ^d   Palmer, James N ^d   Cohen, Noam A ^d,e,f   Harro, Jan M ^a   Lee, Steven K ^c   Miller, Lloyd S ^c   Shirtliff, Mark E ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MONELL CHEMICAL SENSES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17F; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BETA DEFENSIN; BETA-DEFENSIN 3, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NOSE SECRETION; NOSE SMEAR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPERNATANT; UPREGULATION; ADULT; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; NOSE; PHYSIOLOGY;

ADULT; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-DEFENSINS; CARRIER STATE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NOSE; STAPHYLOCOCCUS AUREUS; UP-REGULATION;

EID: 85002772608     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00596-16     Document Type: Article

References (53)

1. Bardan A, Nizet V, Gallo RL. 2004. Antimicrobial peptides and the skin. Expert Opin Biol Ther 4:543-549. http://dx.doi.org/10.1517/14712598.4 .4.543
2. Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI. 1985. Primary structures of three human neutrophil defensins. J Clin Investig 76:1436-1439. http://dx.doi.org/10.1172/JCI112121
3. Lehmann J, Retz M, Harder J, Krams M, Kellner U, Hartmann J, Hohgrawe K, Raffenberg U, Gerber M, Loch T, Weichert-Jacobsen K, Stockle M. 2002. Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection.BMCInfect Dis 2:20. http://dx.doi.org/10 .1186/1471-2334-2-20
4. Jenssen H, Hamill P, Hancock RE. 2006. Peptide antimicrobial agents. Clin Microbiol Rev 19:491-511. http://dx.doi.org/10.1128/CMR.00056-05
5. Doss M, White MR, Tecle T, Hartshorn KL. 2010. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol 87:79-92. http://dx.doi.org/10 .1189/jlb.0609382
6. Zanetti M. 2004. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75:39-48
7. Boman HG. 2003. Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254:197-215. http://dx.doi.org/10.1046/j.1365-2796 .2003.01228.x
8. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. 2005. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 30:385-394. http://dx.doi.org/10.1080/02713680590934111
9. Midorikawa K, Ouhara K, Komatsuzawa H, Kawai T, Yamada S, Fujiwara T, Yamazaki K, Sayama K, Taubman MA, Kurihara H, Hashimoto K, Sugai M. 2003. Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect Immun 71:3730-3739. http://dx.doi.org/10 .1128/IAI.71.7.3730-3739.2003
10. Bals R, Wang X, Wu Z, Freeman T, Bafna V, Zasloff M, Wilson JM. 1998. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Investig 102:874-880. http://dx.doi.org/10 .1172/JCI2410
11. Harder J, Bartels J, Christophers E, Schroder JM. 2001. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 276:5707-5713. http://dx.doi.org/10.1074/jbc .M008557200
12. Huang Q, Yu HJ, Liu GD, Huang XK, Zhang LY, Zhou YG, Chen JY, Lin F, Wang Y, Fei J. 2012. Comparison of the effects of human betadefensin 3, vancomycin, and clindamycin on Staphylococcus aureus biofilm formation. Orthopedics 35:e53-e60
13. Zanger P, Holzer J, Schleucher R, Scherbaum H, Schittek B, Gabrysch S. 2010. Severity of Staphylococcus aureus infection of the skin is associated with inducibility of human beta-defensin 3 but not human betadefensin 2. Infect Immun 78:3112-3117. http://dx.doi.org/10.1128/IAI .00078-10
14. Zanger P, Nurjadi D, Vath B, Kremsner PG. 2011. Persistent nasal carriage of Staphylococcus aureus is associated with deficient induction of human beta-defensin 3 after sterile wounding of healthy skin in vivo. Infect Immun 79:2658-2662. http://dx.doi.org/10.1128/IAI.00101-11
15. van Belkum A, Emonts M, Wertheim H, de Jongh C, Nouwen J, Bartels H, Cole A, Cole A, Hermans P, Boelens H, Toom NL, Snijders S, Verbrugh H, van Leeuwen W. 2007. The role of human innate immune factors in nasal colonization by Staphylococcus aureus. Microbes Infect 9:1471-1477. http://dx.doi.org/10.1016/j.micinf.2007.08.003
16. Fode P, Stegger M, Andersen PS. 2011. Human beta-defensin 3 (DEFB103) and its influence on Staphylococcus aureus nasal carriage. Int J Infect Dis 15:e388-e394. http://dx.doi.org/10.1016/j.ijid.2011.02.003
17. Nurjadi D, Herrmann E, Hinderberger I, Zanger P. 2013. Impaired beta-defensin expression in human skin links DEFB1 promoter polymorphisms with persistent Staphylococcus aureus nasal carriage. J Infect Dis 207:666-674. http://dx.doi.org/10.1093/infdis/jis735
18. Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R. 1997. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 272:13088-13093. http://dx.doi.org/10.1074/jbc.272.20.13088
19. Jann NJ, Schmaler M, Kristian SA, Radek KA, Gallo RL, Nizet V, Peschel A, Landmann R. 2009. Neutrophil antimicrobial defense against Staphylococcus aureus is mediated by phagolysosomal but not extracellular trap-associated cathelicidin. J Leukoc Biol 86:1159-1169. http://dx.doi .org/10.1189/jlb.0209053
20. Bals R, Wang X, Meegalla RL, Wattler S, Weiner DJ, Nehls MC, Wilson JM. 1999. Mouse beta-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. Infect Immun 67:3542-3547
21. Hinrichsen K, Podschun R, Schubert S, Schroder JM, Harder J, Proksch E. 2008. Mouse beta-defensin-14, an antimicrobial ortholog of human beta-defensin-3. Antimicrob Agents Chemother 52:1876-1879. http://dx .doi.org/10.1128/AAC.01308-07
22. Burd RS, Furrer JL, Sullivan J, Smith AL. 2002. Murine betadefensin-3 is an inducible peptide with limited tissue expression and broad-spectrum antimicrobial activity. Shock 18:461-464. http://dx.doi .org/10.1097/00024382-200211000-00013
23. Jiang Y, Yi X, Li M, Wang T, Qi T, She X. 2012. Antimicrobial activities of recombinant mouse beta-defensin 3 and its synergy with antibiotics. J Mater Sci Mater Med 23:1723-1728. http://dx.doi.org/10.1007/s10856-012-4645-z
24. Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. 2008. Identification and biological characterization of mouse beta-defensin 14, the orthologue of human beta-defensin 3. J Biol Chem 283:5414-5419
25. Zhu C, Qin H, Cheng T, Tan HL, Guo YY, Shi SF, Chen DS, Zhang XL. 2013. Staphylococcus aureus supernatant induces the release of mouse beta-defensin-14 from osteoblasts via the p38 MAPK and NF-kappaB pathways. Int J Mol Med 31:1484-1494
26. Archer NK, Harro JM, Shirtliff ME. 2013. Clearance of Staphylococcus aureus nasal carriage is T cell dependent and mediated through interleukin-17A expression and neutrophil influx. Infect Immun 81:2070-2075. http://dx.doi.org/10.1128/IAI.00084-13
27. Kolls JK, McCray PB, Jr, Chan YR. 2008. Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol 8:829-835. http://dx.doi.org/10.1038/nri2433
28. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC
29. National Institutes of Health. 2002. Public Health Service policy on humane care and use of laboratory animals. Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD
30. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, Boelens HA, Hofman A, van Belkum A, Verbrugh HA. 2004. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule." Clin Infect Dis 39:806-811
31. Strommenger B, Kettlitz C, Weniger T, Harmsen D, Friedrich AW, Witte W. 2006. Assignment of Staphylococcus isolates to groups by spa typing, SmaI macrorestriction analysis, and multilocus sequence typing. J Clin Microbiol 44:2533-2540. http://dx.doi.org/10.1128/JCM.00420-06
32. Larsen AR, Stegger M, Sorum M. 2008. spa typing directly from a mecA, spa and pvl multiplex PCR assay-a cost-effective improvement for methicillin-resistant Staphylococcus aureus surveillance. Clin Microbiol Infect 14:611-614. http://dx.doi.org/10.1111/j.1469-0691.2008.01995.x
33. Lee RJ, Kofonow JM, Rosen PL, Siebert AP, Chen B, Doghramji L, Xiong G, Adappa ND, Palmer JN, Kennedy DW, Kreindler JL, Margolskee RF, Cohen NA. 2014. Bitter and sweet taste receptors regulate human upper respiratory innate immunity. J Clin Investig 124:1393-1405. http://dx.doi.org/10.1172/JCI72094
34. Ganz T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3:710-720. http://dx.doi.org/10.1038/nri1180
35. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, Fujikado N, Tanahashi Y, Akitsu A, Kotaki H, Sudo K, Nakae S, Sasakawa C, Iwakura Y. 2009. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30:108-119. http://dx.doi.org/10.1016/j.immuni .2008.11.009
36. van Belkum A, Verkaik NJ, de Vogel CP, Boelens HA, Verveer J, Nouwen JL, Verbrugh HA, Wertheim HF. 2009. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis 199:1820-1826. http://dx.doi.org/10.1086/599119
37. Kluytmans J, van Belkum A, Verbrugh H. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10:505-520
38. Sollid JU, Furberg AS, Hanssen AM, Johannessen M. 2014. Staphylococcus aureus: determinants of human carriage. Infect Genet Evol 21:531-541. http://dx.doi.org/10.1016/j.meegid.2013.03.020
39. Zanger P, Holzer J, Schleucher R, Steffen H, Schittek B, Gabrysch S. 2009. Constitutive expression of the antimicrobial peptide RNase 7 is associated with Staphylococcus aureus infection of the skin. J Infect Dis 200:1907-1915. http://dx.doi.org/10.1086/648408
40. Krishna S, Miller LS. 2012. Innate and adaptive immune responses against Staphylococcus aureus skin infections. Semin Immunopathol 34: 261-280. http://dx.doi.org/10.1007/s00281-011-0292-6
41. Cole AM, Dewan P, Ganz T. 1999. Innate antimicrobial activity of nasal secretions. Infect Immun 67:3267-3275
42. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271-2279. http://dx.doi.org/10.1084/jem .20061308
43. Huang F, Kao CY, Wachi S, Thai P, Ryu J, Wu R. 2007. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J Immunol 179:6504-6513. http://dx.doi.org/10.4049/jimmunol.179.10.6504
44. Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, Bistoni F, d'Enfert C, Vecchiarelli A. 2011. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One 6:e22770. http://dx.doi.org/10.1371/journal.pone.0022770
45. Kao CY, Chen Y, Thai P, Wachi S, Huang F, Kim C, Harper RW, Wu R. 2004. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol 173: 3482-3491. http://dx.doi.org/10.4049/jimmunol.173.5.3482
46. Peric M, Koglin S, Kim SM, Morizane S, Besch R, Prinz JC, Ruzicka T, Gallo RL, Schauber J. 2008. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide inhumankeratinocytes. J Immunol 181:8504-8512. http://dx.doi.org/10.4049/jimmunol.181.12.8504
47. Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, Wheelwright M, Vazirnia A, Zhang X, Steinmeyer A, Zugel U, Hollis BW, Cheng G, Modlin RL. 2009. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 4:e5810. http://dx.doi.org/10.1371/journal.pone.0005810
48. Bals R, Wang X, Zasloff M, Wilson JM. 1998. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A 95:9541-9546. http://dx.doi.org/10.1073/pnas.95.16.9541
49. Cowland JB, Johnsen AH, Borregaard N. 1995. hCAP-18, a cathelin/probactenecin-like protein of human neutrophil specific granules. FEBS Lett 368:173-176. http://dx.doi.org/10.1016/0014-5793(95)00634-L
50. Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H, Gudmundsson GH. 1997. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272:15258-15263. http://dx .doi.org/10.1074/jbc.272.24.15258
51. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, Stahle-Backdahl M. 2003. The cathelicidin anti-microbial peptide LL-37 is involved in reepithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Investig Dermatol 120:379-389. http://dx.doi.org/10.1046/j.1523-1747.2003.12069.x
52. Dunsche A, Acil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S. 2002. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 110:121-124. http://dx.doi.org/10.1034/j.1600-0722.2002 .11186.x
53. Uehara N, Yagihashi A, Kondoh K, Tsuji N, Fujita T, Hamada H, Watanabe N. 2003. Human beta-defensin-2 induction in Helicobacter pyloriinfected gastric mucosal tissues: antimicrobial effect of overexpression. J Med Microbiol 52:41-45. http://dx.doi.org/10.1099/jmm.0.04985-0